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Abstract. We report on the first stages of a clinical study designed to
test elastic-scattering spectroscopy, mediated by fiberoptic probes, for
three specific clinical applications in breast-tissue diagnosis: (1) a
transdermal-needle (interstitial) measurement for instant diagnosis
with minimal invasiveness similar to fine-needle aspiration but with
sensitivity to a larger tissue volume, (2) a hand-held diagnostic probe
for use in assessing tumor/resection margins during open surgery, and
(3) use of the same probe for real-time assessment of the ‘‘sentinel’’
node during surgery to determine the presence or absence of tumor
(metastatic). Preliminary results from in vivo measurements on 31
women are encouraging. Optical spectra were measured on 72 his-
tology sites in breast tissue, and 54 histology sites in sentinel nodes.
Two different artificial intelligence methods of spectral classification
were studied. Artificial neural networks yielded sensitivities of 69%
and 58%, and specificities of 85% and 93%, for breast tissue and
sentinel nodes, respectively. Hierarchical cluster analysis yielded sen-
sitivities of 67% and 91%, and specificities of 79% and 77%, for
breast tissue and sentinel nodes, respectively. These values are ex-
pected to improve as the data sets continue to grow and more sophis-
ticated data preprocessing is employed. The study will enroll up to
400 patients over the next two years. © 2000 Society of Photo-Optical Instru-
mentation Engineers. [S1083-3668(00)00302-6]
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Various types of optical spectroscopy have been investigated
as methods of ‘‘optical biopsy,’’ with a majority of research
efforts focusing on UV-induced fluorescence or Raman spec-
troscopies. ~For a review of the topic, see, for example, Ref. 1
or references contained therein.! Recently, elastic-scattering
spectroscopy ~ESS! ~sometimes called ‘‘diffuse reflectance
spectroscopy’’! has been studied as a method for minimally
invasive optical diagnosis of tissue pathologies, with empha-
sis on distinguishing dysplasia and cancer from normal tissue
or other benign conditions2–4 or for distinguishing different
normal tissue types.5 ESS, when performed using an appro-
priate optical geometry,6,7 is sensitive to the sizes and struc-
tures of the subcellular components that change upon trans-
formation to premalignant or malignant conditions ~e.g., the
nucleus, mitochondria, etc!.8 In work reported to date, clinical
application of the ESS technique has been fundamentally non-
invasive, with access to the tissue mediated by endoscopes2–4
or by means of direct topical access as would be appropriate
for diagnosis on the cervix.9,10
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665-4637; E-mail: ijb@LANL.govd From: http://biomedicaloptics.spiedigitallibrary.org/ on 10/15/2015 Terms Within solid organs, such as the breast, the least invasive
approach requires access through a needle. In screening, most
early breast cancers are detected when an abnormality is seen
on mammography, although some patients may detect a lump
themselves ~palpation!. In either case, before any treatment is
initiated, the diagnosis must be confirmed by fine-needle as-
piration cytology ~FNA! or biopsy ~which is often done as an
open procedure!. Approximately 50 000 diagnostic lumpecto-
mies are performed annually in the U.S. Of those, only about
12 000 turn out to be malignant when histology is performed
on the excised tissue by a pathologist.11 If it had been known
in advance that the remaining 38 000 lesions were benign, the
potentially disfiguring surgery could have been avoided, along
with the trauma and cost, as many benign lesions resolve
spontaneously in time, without intervention. A core biopsy,
through a large-gauge needle, is a frequent alternative to sur-
gical resection or lumpectomy for biopsy. Although less in-
vasive than core biopsy, FNA is only infrequently used in the
U.S. because false-negative rates with FNA are often in the
range of 12%–15%,12,13 and its reliability is under critical
review. This is due to the heterogeneity of breast lesions and
the relatively small number of cells accessed by FNA. Despite
having the same level of invasiveness as FNA, the ESS
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Downloademethod poses the potential advantage of immediate diagnosis,
and there is the possibility of improved sensitivity when com-
pared with FNA, due to the larger tissue volume that is sensed
by the ESS method. If the optical biopsy technique based on
ESS proves sufficiently reliable, it gives an immediate result,
which minimizes the time a patient must wait for a diagnosis
and might make it realistic to treat a small cancer at the same
clinic visit. This will reduce patient anxiety and reduce costs
for the large number of patients who have suspicious areas
seen on mammography. Image-guided optical biopsy either
with magnetic resonance, ultrasound, or conventional mam-
mography could prove particularly valuable for patients with
more than one suspicious area.
However, two other applications of ESS diagnosis to
breast cancer may provide even greater patient benefits than
the transdermal needle measurement. For open surgery proce-
dures, the first of these is the object of our effort to develop a
probe for the surgeon to use during breast-conserving surgery
~wide local excision or partial mastectomy! for determining
the status of the resection margins ~the tissue surface, or ‘‘tu-
mor bed,’’ that is left after the suspect tissue has been ex-
cised! in real time. In current surgical practice, especially
when the tumor limits are not clearly visible, the surgeon ~and
anesthetized patient! are required to wait for pathology results
on a frozen section of the excised tissue to determine if
tumor-free margins of excision have been established. Imme-
diate frozen-section pathology is not always available, and, in
real practice, with delayed pathology positive margins are
found in as many as 20%–55% of all breast-conserving
surgeries,14 requiring a second surgical procedure.
The other potentially important surgical application being
investigated in this study is real-time assessment of a ‘‘senti-
nel’’ lymph node in the axilla. For years, there has been con-
troversy about how the axilla should be treated in breast can-
cer patients. Recent research has shown that if the main node
in the axilla draining a tumor area, called the sentinel node, is
removed and does not show cancer, then the chances of any
other nodes in the axilla showing cancer are approaching
1%.15 Thus, if the sentinel node does not show cancer, the rest
of the axillary nodes can be left in place, but if it does show
cancer, then a full surgical axillary-node clearance must be
done. The sentinel node can be identified by injecting a radio-
active marker and then scanning the axilla about 24 h later
~during surgical preparation! or by using a dye such as meth-
ylene blue, which can be easily detected in tissue during sur-
gery. The ESS method may be able to provide immediate
assessment of the sentinel node during surgery.
Our diagnostic study is coupled, utilizing the same patient
cohort, with a study of minimally invasive optical treatment.
In the case of focal lesions, treatment can be accomplished
using interstitial laser photocoagulation with laser energy
from a diode laser, again mediated by fiber optics through a
transdermal needle, to nonsurgically treat both adenocarcino-
mas and fibroadenomas. Results for that part of the study will
be reported in separate publication~s!.
2 Materials and Methods
The clinical instrumentation based upon elastic-scattering
spectroscopy is essentially similar to that described in publi-
cations on earlier clinical studies.2,3 The system ~see Figure 1!222 Journal of Biomedical Optics d April 2000 d Vol. 5 No. 2
d From: http://biomedicaloptics.spiedigitallibrary.org/ on 10/15/2015 Terms consists of a pulsed xenon-arc lamp ~EG&G! for the light
source, a PC-compatible spectrometer, ~a modified version of
a spectrometer manufactured by Ocean Optics, Dunedin, FL!,
which employs a linear charge-coupled device ~CCD! array
for detection, an optical-fiber based probe, and a laptop com-
puter for system control and data display. The wavelength
range of the system is from 300 to 900 nm, but the range used
for these studies is 330–750 nm, which covers the near-UV-
visible part of the electromagnetic spectrum. As depicted in
Figure 2, the probe is designed to be used in ~gentle! optical
contact with the tissue and incorporates two optical fibers,
which are selected for their broadband light transmission over
the spectral range used in the study. The output of the arc
lamp is coupled to the illumination fiber, with a core diameter
of 400 mm, which transmits the light to the tissue target site.
A second, adjacent and parallel fiber within the probe, with a
core diameter of 200 mm, collects a small fraction of the
scattered light from the tissue. The collected light is then
guided to the spectrometer where an optical spectrum is gen-
erated for further processing. For all of the measurements in
this study, the probe design fixes the center-to-center separa-
tion of the collection and delivery fibers at 350 mm, at the tip
of the probe. For this probe geometry, the volume of tissue
Fig. 1 Schematic diagram of the principal components of the ESS di-
agnostic system. All components (except for the fiber probe) are lo-
cated inside a small, portable chassis.
Fig. 2 Depiction of the optical geometry for the fiberoptic probe.of Use: http://spiedigitallibrary.org/ss/TermsOfUse.aspx
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mately 500 mm long, 300 mm wide and 300 mm deep. This
has been determined from computational simulations using
our Monte Carlo code, which incorporates Mie theory for the
details of the scattering events.6
In clinical use the tip of the fiber probe is momentarily
placed in contact with the suspect tissue, and the measurement
is activated, at the keyboard or with a foot pedal. The system
automatically takes a background (ambient1‘‘dark’’) mea-
surement without firing the lamp, followed immediately
~within 100 ms! by an ESS measurement with the pulsed lamp
being triggered, and then subtracts the background spectrum
from the ESS spectrum. The entire measurement process, i.e.,
activating the spectrometer, triggering the arc lamp, reading
the detector array with an analog/digital ~A/D! converter, etc.,
is computer controlled by a laptop PC, and can be activated
with a foot pedal. This allows both accurate and reproducible
measurements within the clinical setting. Furthermore, it also
provides the clinician with the advantages of rapid data acqui-
sition and a graphical display for inspection. Typical data ac-
quisition and display time is less than 1 s for each site mea-
surement. More specific details about the basic concepts of
ESS, and discussion about the optical system and the design
philosophy of the optical fiber probe, can be found in previous
publications.6,16,17
Prior to any clinical measurements the ESS system and
probe are calibrated with a reflectance standard. The reflec-
tance standard ~Spectralon™, Labspere, Inc., North Sutton,
NH! has a spectrally flat, diffuse reflectance .98%, over the
entire wavelength range of the system. The purpose of refer-
encing the system to a known standard is to allow the normal-
ization of spectral data against the overall system response.
This technique effectively minimizes any variations in the
system response due to variations in the spectral transmission
among different probes, thermal effects, coupling efficiency
of the fiber probe, drifts in detector/spectrometer response,
etc. The reference standard and probes are sterilized by auto-
clave, and the housing of the reference standard protects it
from any airborne contaminants during surgery.
Two different optical-probe configurations have been fab-
ricated for use in the clinical program. Both probes incorpo-
rate the same ‘‘standardized’’ optical design, which specifies
the diameters of the illumination and collection fibers, as well
as the distance between the centers of the fibers, as specified
above. It should be noted that details of the probe’s optical
design, including the fiber sizes and separation, have a signifi-
cant effect upon the characteristic spectra obtained for a par-
ticular tissue. Therefore, these parameters are standardized for
each clinical study in order to optimize the sensitivity of the
system to tissue variations and also to prevent spectral varia-
tions due to instrumental artifacts. The main difference be-
tween the two probes designed for this study is to be found in
the mechanical housing of the probe, allowing each to be
optimized for the different specific clinical procedures. For
interstitial ~transdermal! measurements the probes have a
small-diameter ~<1 mm! stainless-steel outer sheath, which
houses the optical fibers. The outer diameter of these probes
was carefully chosen to be compatible with the inner bore of
current core-biopsy needles in use at the clinics, so that a
probe could safely and easily be passed down the needle and
presented to the tumor tissue under investigation. The secondd From: http://biomedicaloptics.spiedigitallibrary.org/ on 10/15/2015 Terms probe design incorporates a larger stainless-steel sheath, ;5
mm in diameter, to house the optical fibers, with no change to
the fiber dimensions or separation. This creates an ergonomi-
cally convenient, pen-like design, which is utilized, hand held,
for optical measurements during open surgery, when both re-
sected tumor margins and lymph nodes are addressed.
3 In Vivo Measurement Procedures
All clinical measurements reported here have been performed
at the Middlesex Hospital, University College London Hospi-
tals, UK. Histological examination of all tissue samples has
been performed by the same pathologist ~S.L.!. Before any in
vivo measurements were made, ex vivo tissue samples were
obtained from resected breast specimens from 15 patients and
were measured with the ESS system. These initial findings
were used to optimize the operational settings of the system,
and also helped to establish protocols for marking the optical
biopsy sites for histological examination and correlation. All
in vivo measurements are performed under a protocol ap-
proved by the Ethical Review Board of the Middlesex Hospi-
tal. Prior to surgery every patient within the study is informed
about the research program, and informed consent for data to
be taken is provided by the patient. As mentioned in the pre-
vious section, three separate areas are currently under inves-
tigation, and each warrants discussion due to the techniques
employed in order to obtain the ESS spectra.
For interstitial measurements with the ESS system, a core-
biopsy ~Tru-cut™! needle is guided into the palpable lesion,
sometimes with the aid of ultrasound or magnetic-resonance
imaging. The appropriate ESS optical probe is then inserted
through the needle and gently placed in direct contact with the
tissue at the needle’s distal end. After the optical measure-
ment has been made, the fiber probe is withdrawn, and the
inner component of the biopsy tool is reinserted and a core
biopsy is then taken from the same site, without moving the
needle. This produces a small worm-shaped biopsy sample,
one end of which has been measured optically. The other end
of the core sample ~which is opposite to the end of the sample
that was interrogated by the ESS probe! is marked with India
ink so that proper orientation is preserved and identification of
the end examined with the ESS probe can be maintained and
correlated with histology.
Following the core-biopsy procedures, some of the patients
immediately undergo surgery in order to have the tumor re-
sected. In these and other surgical cases ~not preceded by core
biopsy!, and depending upon the exact nature of the surgical
procedure, measurements are taken from one or more loca-
tions of the tumor bed, during and immediately after resec-
tion. Each optical measurement is followed by a small surgi-
cal biopsy of the same site, and the biopsy samples are coded
to correlate with the ESS probe measurements.
With a subset of the surgical patients, assessment of the
sentinel node is performed in order to determine the presence
of metastatic disease. ~In a number of patients more than one
node was assessed.! During the surgical procedure the senti-
nel node is located with the aid of radioactive tracer and/or
blue dye ~both injected previously into the tissue space near
the tumor!. The node is resected and cut in half, and ESS
measurements are made on one or more sites on the cut sur-
face of the node. Once again, the ESS measurement sites areJournal of Biomedical Optics d April 2000 d Vol. 5 No. 2 223
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ing histopathology information about the specific locations
measured.
4 Methods of Classification
The data reported here were taken on the first 31 patients of
the study ~which will eventually enroll up to 400 patients over
the next two years!, with breast-tissue measurements ~either
as an interstitial measurement or during surgery! being made
on 24 of them and lymph-node measurements ~during sur-
gery! on 21 of them. Thus, both breast-tissue measurements
and sentinel-node measurements were made on many, but not
all, of the patients. The numbers of patients and measure-
ments are summarized in Table 1. The last two columns list
the histopathology designations for the sites measured opti-
cally, i.e., the number of true positives and true negatives. In
many cases two or three optical measurements were made for
a given biopsy site to test repeatability of the spectra. How-
ever, it is not appropriate to treat multiple spectra from the
same biopsy site as independent measurements, as this could
result in incorrectly high or low sensitivity and/or specificity.
Consequently, in such cases the multiple spectra ~which were
very similar! were averaged together and treated as a single
spectrum. Thus, one spectrum is correlated with each biopsy
site. An effort was always made to mark precisely each site of
optical measurement, so that corresponding histopathology
could be properly correlated.
Table 1 Histopathology of optically measured tissue sites.
Number of
patients
Number of
biopsies
Number of
cancer sites
Number of
normal sites
Breast tissue 24 72 13 59
Sentinel nodes 21 54 12 42224 Journal of Biomedical Optics d April 2000 d Vol. 5 No. 2
d From: http://biomedicaloptics.spiedigitallibrary.org/ on 10/15/2015 Terms Figures 3 and 4 show examples of tissue spectra, malig-
nant and nonmalignant, for breast tissue and sentinel nodes,
respectively. The spectra in Figure 3 are examples that are
representative of some but not all of the data. It would be
misleading to assume otherwise, given the heterogeneity of
breast tissue ~glandular, adipose, connective, fibrous, ductal
structures, etc.! and the resulting large spectral variations.
Consequently, it would be risky to base diagnosis directly on
a model for any specific/common signature causes. For ex-
ample, Figure 3 does not show a difference in hemoglobin
saturation between normal breast tissue and ductal carcinoma
in situ ~DCIS!, although there is evidence of more perfusion
in the DCIS, which is expected. ~On the other hand, Figure 4
does indicate some desaturation for the metastatic sentinel
node, and the spectra are more representative of other node
spectra, since nodes are less heterogeneous.! Reduced satura-
tion can indicate cancer indirectly because necrotic regions
are more likely to be cancer than benign, but DCIS is an early,
pre-invasive stage, and does not generally invoke necrosis.
Thus, reduced saturation can be indicative of cancer ~although
other conditions can also, more rarely, produce necrosis!, but
good saturation is not a reliable indicator of benign condi-
tions. Artificial-intelligence pattern-recognition ~AI-PR!
methods are well suited for spectral classification when
model-based analysis is made difficult by the large number of
necessary input parameters resulting from heterogeneity.
Nonetheless, there certainly are some spectral indicators that
are understood, as discussed below, and we have ensured that
the input parameters ~derived from the spectra! for our AI
analyses contain that information.
Two different AI-PR methods of spectral classification
have been employed to assess the degree of correlation be-
tween pathology and spectral pattern differences: artificial
neural networks and hierarchical cluster analysis. Artificial
neural networks ~ANNs! were selected for study because of
the expectation by our group and other researchers4 that
ANNs would prove to be a generally useful method of tissue
spectral classification. ANNs ~and other AI-PR methods! areFig. 3 Examples of ESS spectra for normal and malignant breast-tissue conditions.of Use: http://spiedigitallibrary.org/ss/TermsOfUse.aspx
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DownloadeFig. 4 Examples of ESS spectra for a reactive node, without tumor, and for node containing metastatic tumor.known to be well suited for classification in systems where
model-based classification is difficult.18 As stated above, such
is the case with ESS spectra of breast tissue because of its
remarkable heterogeneity of tissue types. In light of this ex-
pectation, there was interest in our group to evaluate the rela-
tive merits of ANNs in ESS spectral analysis. Hierarchical
cluster analysis ~HCA! was also selected for study because it
can serve as an alternative to the many approaches to classi-
fication that provide unbounded class regions ~including
ANNs, as well as linear discriminant analysis, regression
analysis, etc.!. The problem of unbounded class regions, and
the benefits of using cluster analysis to avoid this problem, are
discussed in detail by Osbourn et al.19 In general, the problem
with unbounded class regions is that a new sample will be
classified in one of the available classes of a previously
trained system, even if the input parameters of this new
sample differ markedly from the other samples in the class to
which it is assigned. This is not a problem when new samples
are expected to be reasonably similar to previous samples.
With optical biopsies, however, a number of variables can
significantly alter the measured spectra. In addition to tissue
heterogeneity, and even with relatively homogeneous tissue
types, there can be experimental factors such as the presence
of fluid ~especially blood! trapped under the probe tip, or
simply as a consequence of improper probe contact with tis-
sue. It would thus be beneficial for a classification technique
to be able to recognize samples that may have been adversely
affected by such variables ~i.e., ‘‘outliers:’’ samples that dif-
fer markedly from previous samples!. Having bounded class
regions, such as those produced through HCA, provides this
ability to reject outliers. A more detailed description and com-
parison of these artificial intelligence methods for classifica-
tion of tissue spectra for several different organ areas is the
subject of a future publication currently in preparation.
Although both ANN and HCA methods are intrinsically
statistical-based classification methods, some preprocessing or
weighting of input parameters can be implemented to ‘‘as-
sist’’ classification when some things about the underlyingd From: http://biomedicaloptics.spiedigitallibrary.org/ on 10/15/2015 Terms tissue optical properties are known. ~Such preprocessing can,
in effect, combine benefits of both statistical-based analysis
and model-based analysis.! In its simplest form this means
that the input parameters for training the AI methods, which
are derived from the raw spectra, should be structured so as to
include the spectral information known to have diagnostic rel-
evance. For example, the presence of adipose ~fatty! tissue in
the measured volume is much more frequently associated with
normal or benign breast conditions ~for a given biopsy site!
than with adenocarcinoma. Especially in postmenopausal
women, and in mixed tissues, a developing adenocarcinoma
will often ‘‘push’’ the fat out of the tissue volume where
growth is occurring. Since adipose tissue has the characteris-
tic absorption feature of beta carotene, the spectral bands con-
taining that feature can be accounted for. ~The absorption fea-
ture of beta carotene ~450–500 nm! can be seen in both the
fibro-fatty and normal spectra in Figure 3.! Another example
is the mean redox state of the hemoglobin in the tissue. He-
moglobin desaturation is generally indicative of necrotic/
malignant lesions, although the obverse is not true, and hy-
pervascularization more frequently accompanies malignant
tissue than normal or benign conditions. In short, it is valuable
to include enough detail of the beta carotene and hemoglobin
bands among the AI-PR input parameters. Finally, broad
~large-spectral-range! slope changes are expected for malig-
nant conditions in glandular tissue due to enlarged and denser
nuclei, and other scattering differences are expected among
tissue types.
For the data analyses presented here, some model-based
preprocessing was implemented to ensure sensitivity to
known factors, but no weighting of any specific parameters
was implemented at this stage. This and other methods of data
preprocessing can improve the classification accuracy, and
will be treated more extensively in a future publication.
5 Data Processing and Analysis Results
For all analyses reported here the spectra from breast tissues
and sentinel nodes were analyzed separately since they areJournal of Biomedical Optics d April 2000 d Vol. 5 No. 2 225
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spectra were preprocessed by first normalizing each spectrum
to the same total integral over the spectral range of 330–750
nm. Sentinel-node spectra were normalized for the range
330–590 nm. ~See discussion below.! Thus, only spectral
shapes were compared. These normalized spectra comprise
information on both the spectral dependence of scattering pa-
rameters and absorption bands, but not total scattering effi-
ciencies. Such data treatment eliminates concerns about dif-
ferences in optical coupling and/or transmission among the
several fiber probes used, although any potentially useful in-
formation in the total scattering efficiency is, admittedly, also
lost. In the case of sentinel nodes, many exhibited strong ab-
sorption due to the presence of methylene blue dye ~Patent
Blue™!, which had been used to assist the surgeon in locating
the node during surgery. Therefore, sentinel-node spectra
were also treated to subtract the feature of that absorption
band, and were analyzed for the range of 330–590 nm.
In presenting the statistical results, sensitivity and specific-
ity are defined in the standard way
Sensitivity[SE=TP/(TP+FN),
Specificity[SP=TN/(TN+FP),
where TP, FP, TN, and FN represent the numbers of true
positives, false positives, true negatives, and false negatives,
respectively, as determined by the corresponding histopathol-
ogy.
5.1 ANN Classification
For ANN classification the normalized spectra were divided
into 21 wavelength bands of 20 nm width ~330–750 nm!, with
some of the intervals being smaller for sentinel-node spectra
because of the reduced total spectral range ~330–590 nm!, and
an average spectral intensity for each interval was calculated.
For classification of breast-tissue spectra we also included
slopes of the intervals as input parameters, and although more
sophisticated ANNs can handle a large number of input
nodes, ours was limited to about 20. Therefore, for breast-
tissue spectra, principal component analysis was performed
on the interval intensities to establish a smaller number of
input parameters.20 The resulting smaller number ~4–6! of
principal components based on spectral intensities were com-
bined with a number of slopes for various spectral intervals,
for a total of 12–16 input parameters.
With ANN classification a variety of network designs and
transfer functions between neuron layers are possible.21 The
analyses presented here used a relatively simple flat, three-
layer network, with input and output layers and one hidden
layer of neural nodes, or ‘‘neurodes.’’ As mentioned above,
the input layer had 12–16 input parameters ~neurodes! and the
output layer always had two parameters, for malignant and
nonmalignant conditions. The choice for the number of
hidden-layer neurodes is somewhat arbitrary, and a typical
starting point is to set it at half the total of input and output
parameters, although sometimes a somewhat larger number is
chosen if training is too slow. The transfer function ~between
layers! chosen for these analyses is a unipolar sigmoid ~from
0 to 1!, which is often used for parameters that can have
smoothly varying values.21 Network training was accom-226 Journal of Biomedical Optics d April 2000 d Vol. 5 No. 2
d From: http://biomedicaloptics.spiedigitallibrary.org/ on 10/15/2015 Terms plished by ‘‘error back propagation,’’ wherein the correct di-
agnoses ~from histopathology! are presented at the output
layer, and the network is run ~transfer functions are varied! to
minimize the error between the classified output and the
known parameter. Eighty percent of the data samples where
selected randomly for training and the remaining 20% were
used for testing. This was repeated five times with disjoint
testing sets, each with a different 20% of the samples, so that
all of the data samples were used for testing, but none were
used for both training and testing in the same run. Statistics
were derived from the average of all five runs. Given the
modest size of the data set, better statistics might have been
achieved by the ‘‘leave-one-out’’ method where only one data
sample is used for testing ~and n21 are used for training! and
repeating the process n times, but this would have taken pro-
hibitively long computer time.
5.2 HCA Classification
For HCA classification of breast-tissue spectra, the spectra
were again divided into 20 nm intervals, and a preliminary
cluster-template analysis was performed, as described below,
in order to pre-select a subset of interval intensities to be used
for input parameters. Similarly, preliminary template analysis
was also performed with interval slopes in order to pre-select
a reduced number of slopes as input parameters. A combina-
tion of these pre-selected intensities and slopes was then used
as the set of input parameters for the full HCA analysis. For
sentinel-node spectra only the interval intensities were used as
input parameters, without any pre-selection.
With the hierarchical cluster analysis method the ‘‘train-
ing’’ consists of trying all possible different combinations of
the input parameters, using multidimensional pattern recogni-
tion schemes to find clusters with no a priori input of actual
classifications, and then comparing the resulting clusters with
the known classifications of their members. Different criteria
are possible for determining the multidimensional Euclidian
‘‘distance’’ between a sample point and a given cluster: near-
est neighbor, farthest neighbor, or average distance.20 For the
analyses presented we chose the average-distance method.
The combination of input parameters that yields the clusters
of samples that best agree with each other, by having the same
histology classifications, is the one that is chosen. For a given
number of input parameters HCA generally requires more
data than ANNs for statistical stability of the clusters ~out-
puts!. However, training can be faster than for ANNs. Once
the input parameters for the best clustering are established, a
new data sample can be tested for those parameters, to see
which ~if any! cluster it falls into. With our modest-sized data
sets, and with the multiple input parameters required, the clus-
ters found are sensitive to the specific choice of training set.
Therefore, instead of an 80/20 split of the data, we applied the
leave-one-out method, as described above, and the statistics
are determined from the sum of all of the leave-one-out tests.
The results of data analysis are summarized in Tables 2
and 3. It can be seen that with the HCA method a few samples
appear as unclassifiable, rather than as false positives or false
negatives. It is especially interesting that, upon examination
of the individual unclassified samples, about half of these out-
liers corresponded to samples that were classified incorrectly
by ANN. The resulting sensitivities and specificities wereof Use: http://spiedigitallibrary.org/ss/TermsOfUse.aspx
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yielded significantly better sensitivity ~91%! than ANN
~58%!, albeit at the cost of somewhat reduced specificity. It is
our expectation that with adequately large data sets HCA with
properly chosen input parameters will generally yield similar
or better sensitivity and specificity, as compared with ANNs,
but with HCA having the advantage of identifying ouliers as
difficult to classify, rather than blindly forcing a classification.
We believe this is a more realistic approach for clinical appli-
cation of any new diagnostic method, and is comparable to
other clinical measurement situations: for example, an invalid
EEG measurement resulting when an electrode has poor con-
tact. As expected with data sets for which there were signifi-
cantly more negatives than positives but comparable accu-
racy, the negative predictive values ~NPV! ~87%–96%! were
significantly higher than the positive predictive values ~PPV!
~40%–75%!, where NPV[TN/~TN1FN!, and
PPV[TP/~TP1FP!.
6 Discussion and Problems Encountered
It is not the purpose of this paper to present a detailed discus-
sion of the structures and functions of different artificial-
intelligence, pattern-recognition schemes for classification of
tissue spectra, but rather to present the results of their imple-
mentation, with minimal refinement, for these preliminary
data of our breast-cancer study. Although our ANN was lim-
ited to about 20 input parameters, with some ANN codes it is
Table 2 Classifications for breast-tissue spectra.
ANN HCA
Number of specimens showing cancer
histologically
13 13
Number of cancers optically diagnosed
as cancer (true positives)
9 8
Number of cancers optically diagnosed
as normal (false negatives)
4 4
Number of cancers with an
indeterminate optical diagnosis
(HCA only)
1
Sensitivity (%) 69% 67%
Number of specimens found normal
histologically
59 59
Number of normals optically diagnosed
as normal (true negatives)
50 44
Number of normals optically diagnosed
as cancer (false positives)
9 12
Number of normals with an
indeterminate optical diagnosis
(HCA only)
3
Specificity (%) 85% 79%
% Classified (HCA only) 91.5%d From: http://biomedicaloptics.spiedigitallibrary.org/ on 10/15/2015 Terms possible to have as many as 250 input parameters, which
would have permitted us to present every spectral resolution
element, for each spectrum, to a separate input node. This
would have permitted capturing all spectral features. Also, a
variety of other improvements and refinements are possible,
including variations in the design of the ANN, and more so-
phisticated data preprocessing and choice of input parameters
for HCA. A careful discussion of the relative merits of AI
methods for tissue-spectra classification will require a full
separate publication, which ~as mentioned above! is in prepa-
ration. Also, with HCA robust clustering requires that the
number of samples be much greater than the number of input
parameters. For the sizes of our data sets this condition was
marginally met, and we expect significant improvement in the
statistics as data sets grow. Nonetheless, we believe these pre-
liminary results are compelling enough to merit presentation
to the scientific community.
In actual clinical implementation of the ESS instrumenta-
tion, it became evident that some attention must be given to
avoiding excessive amounts of blood on the tip of the fiber
probe, as this can obscure information about the amount of
tissue perfusion, or even block much of the scattering spectral
information ~due to the strong absorption by hemoglobin!.
Thus, it was sometimes necessary to sponge, or rinse with
saline, the surgical resection surface to be measured, and/or to
wipe the tip of the probe. Also, for sentinel nodes the accu-
racy in co-registration between optical and histology sites left
some uncertainty when only a small region of the node exhib-
Table 3 Classifications for sentinel-node spectra.
ANN HCA
Number of specimens showing cancer
histologically
12 12
Number of cancers optically diagnosed
as cancer (true positives)
7 10
Number of cancers optically diagnosed
as normal (false negatives)
5 1
Number of cancers with an
indeterminate optical diagnosis
(HCA only)
1
Sensitivity (%) 58% 91%
Number of specimens found normal
histologically
42 42
Number of normals optically diagnosed
as normal (true negatives)
39 26
Number of normals optically diagnosed
as cancer (false positives)
3 8
Number of normals with an
indeterminate optical diagnosis
(HCA only)
8
Specificity (%) 93% 76.5%
% Classified (HCA only) 83.3%Journal of Biomedical Optics d April 2000 d Vol. 5 No. 2 227
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Downloadeited metastasis. Improvements are planned for the co-
registration between optical measurement and histology for
sentinel nodes.
Another problem encountered on a few occasions was that
the ambient lighting of the surgical suite ~with the high-
intensity directed-beam lighting typically found in theater!
would occasionally cause too much scatter through tissue into
the collection fiber of the probe, using up much of the detec-
tor’s dynamic range, and making it difficult for the system to
perform an accurate background subtraction. This was rem-
edied by either having the surgeon momentarily shadow the
strong light from the measurement site, or by a redesign of the
probe fixture to incorporate a small shadow mask. ~Of course,
the strong lights could be temporarily aimed away from the
surgery or reduced in intensity while the ESS measurements
are being made, but we wished to minimize any inconve-
nience to the surgical team.!
Finally, in the development of any new diagnostic tech-
nique, the accuracy and robustness of the ‘‘gold’’ standard,
histopathology, are always a concern. In our case all pathol-
ogy reports were provided by a specialist breast pathologist
~S.L.! of the University College London Hospitals. ~For the
purposes of these analyses, ductal carcinoma in situ ~DCIS!
was always classified as cancer, since the treatment conse-
quences are the same regardless of whether the DCIS already
shows signs of invasiveness or not.! Careful attention has
been paid to adequacy of tissue samples, correlation with op-
tical measurement sites, and consistency of pathology report-
ing terminology, although further improvements are planned.
As the program enlarges, and incorporates other medical cen-
ters, agreement among pathologists will be addressed, and
slides will be read by multiple pathologists. Methods will be
assessed to resolve conflicting reports. Nonetheless, the reli-
ability of histopathology being less than 100%, this type of
correlation is fundamentally limited in accuracy, and determi-
nation of the ultimate capability of the new method requires
long-term outcome studies.
7 Conclusions
We have described a research program designed to test the
value of elastic-scattering spectroscopy as a real-time diag-
nostic tool and as a diagnostic aid to surgical/therapeutic pro-
cedures for breast cancer. We have presented, as preliminary
data, the results from the first 31 patients of a larger program.
The modest sizes of the data sets notwithstanding, the results
of spectral classification by two different methods of ‘‘artifi-
cial intelligence’’ pattern recognition show promise for good
agreement with pathology. This allows us to be hopeful that
as the data sets grow, we will be able to successfully test the
predictive capabilities of already trained spectral classification
schemes.
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